Eli Lilly and Company today announced that Kimberly Blackwell, M.D., one of the nation’s leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.
Dr. Blackwell is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center. She also serves as the co-director of the Duke women’s cancer program, associate director for strategic relations for the Duke Cancer Institute, research scholar for Susan G. Komen, and senior strategist for the Duke Innovation and Entrepreneurship Program. She will report to Levi Garraway, M.D., Ph.D., senior vice president, Global Development & Medical Affairs of Lilly Oncology.
“We are pleased and honored to welcome Dr. Blackwell to Lilly,” said Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology. “She is highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programs that resulted in numerous groundbreaking regulatory approvals in the oncology sector.”
“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”
Source: Eli Lilly and Company
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
